Prevymis Shows Effective CMV Protection After Kidney Transplant

By Gina ShawKidney transplant recipients who received letermovir (Prevymis, Merck) for cytomegalovirus (CMV) prophylaxis experienced similar virologic protection but significantly less myelosuppression compared with those treated with valganciclovir, according to the results of a poster (P-2108).The study, presented by Ismael Aguirre, PharmD, a pharmacy resident at Oregon Health & Science University (OHSU), in Portland, compared real-world outcomes for the two antiviral agents following the